Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Financing Cash Flow

EDITAS MEDICINE, INC. (EDIT) reported Financing Cash Flow of $117.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05

  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $117.53M, a 1485.74% increase year-over-year.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $17.33M, a 68.79% decline year-over-year.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $17.17M.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for fiscal 2025 was $40.47M, a 27.77% decline from fiscal 2024.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for fiscal 2024 was $56.03M, a 52.54% decline from fiscal 2023.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for fiscal 2023 was $118.04M, a 9093.07% increase from fiscal 2022.
  • EDITAS MEDICINE, INC. net cash provided by (used in) financing activities for fiscal 2022 was $1.28M, a 99.54% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30$117.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$117.53M
10-Q · filed 2026-08-05
$134.86M
derived: sum of 3 quarters · filed 2026-08-05
$152.03M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$0.00
10-Q · filed 2026-05-05
$17.33M
derived: sum of 2 quarters · filed 2026-05-05
$34.49M
derived: sum of 3 quarters · filed 2026-05-05
$41.91M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$17.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$34.49M
derived: sum of 2 quarters · filed 2026-03-09
$41.91M
derived: sum of 3 quarters · filed 2026-08-05
$40.47M
10-K · filed 2026-03-09
2025-09-30$17.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$24.58M
derived: sum of 2 quarters · filed 2026-08-05
$23.14M
10-Q · filed 2025-11-10
$78.66M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$7.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$5.97M
10-Q · filed 2026-08-05
$61.49M
derived: sum of 3 quarters · filed 2026-08-05
$61.49M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$1.44M
10-Q · filed 2026-05-05
$54.08M
derived: sum of 2 quarters · filed 2026-05-05
$54.08M
derived: sum of 3 quarters · filed 2026-05-05
$54.40M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$55.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$55.51M
derived: sum of 2 quarters · filed 2026-03-09
$55.84M
derived: sum of 3 quarters · filed 2026-03-09
$56.03M
10-K · filed 2026-03-09
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$322.00K
derived: sum of 2 quarters · filed 2025-11-10
$514.00K
10-Q · filed 2025-11-10
$1.03M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$322.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$514.00K
10-Q · filed 2025-08-12
$1.03M
derived: sum of 3 quarters · filed 2025-08-12
$1.03M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$192.00K
10-Q · filed 2025-05-12
$706.00K
derived: sum of 2 quarters · filed 2025-05-12
$706.00K
derived: sum of 3 quarters · filed 2025-05-12
$118.23M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$514.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
$514.00K
derived: sum of 2 quarters · filed 2025-03-05
$118.04M
derived: sum of 3 quarters · filed 2025-03-05
$118.04M
10-K · filed 2025-03-05
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04
$117.53M
derived: sum of 2 quarters · filed 2024-11-04
$117.53M
10-Q · filed 2024-11-04
$118.14M
derived: sum of 4 quarters · filed 2025-03-05
2023-06-30$117.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$117.53M
10-Q · filed 2024-08-07
$118.14M
derived: sum of 3 quarters · filed 2025-03-05
$118.22M
derived: sum of 4 quarters · filed 2025-03-05
2023-03-31$0.00
10-Q · filed 2024-05-08
$619.00K
derived: sum of 2 quarters · filed 2025-03-05
$699.00K
derived: sum of 3 quarters · filed 2025-03-05
$1.07M
derived: sum of 4 quarters · filed 2025-03-05
2022-12-31$619.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
$699.00K
derived: sum of 2 quarters · filed 2025-03-05
$1.07M
derived: sum of 3 quarters · filed 2025-03-05
$1.28M
10-K · filed 2025-03-05
2022-09-30$80.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
$447.00K
derived: sum of 2 quarters · filed 2023-11-03
$665.00K
10-Q · filed 2023-11-03
$1.72M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$367.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
$585.00K
10-Q · filed 2023-08-02
$1.64M
derived: sum of 3 quarters · filed 2024-02-28
$4.14M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31$218.00K
10-Q · filed 2023-05-05
$1.27M
derived: sum of 2 quarters · filed 2024-02-28
$3.77M
derived: sum of 3 quarters · filed 2024-02-28
$20.85M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31$1.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$3.55M
derived: sum of 2 quarters · filed 2024-02-28
$20.64M
derived: sum of 3 quarters · filed 2024-02-28
$282.11M
10-K · filed 2024-02-28
2021-09-30$2.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$19.58M
derived: sum of 2 quarters · filed 2022-11-02
$281.05M
10-Q · filed 2022-11-02
$290.15M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$17.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$278.55M
10-Q · filed 2022-08-03
$287.65M
derived: sum of 3 quarters · filed 2023-02-22
$288.48M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31$261.47M
10-Q · filed 2022-05-04
$270.57M
derived: sum of 2 quarters · filed 2023-02-22
$271.39M
derived: sum of 3 quarters · filed 2023-02-22
$482.55M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$9.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$9.92M
derived: sum of 2 quarters · filed 2023-02-22
$221.07M
derived: sum of 3 quarters · filed 2023-02-22
$224.12M
10-K · filed 2023-02-22
2020-09-30$822.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$211.97M
derived: sum of 2 quarters · filed 2021-11-09
$215.02M
10-Q · filed 2021-11-09
$299.59M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$211.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$214.20M
10-Q · filed 2021-08-05
$298.77M
derived: sum of 3 quarters · filed 2022-02-24
$342.12M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$3.05M
10-Q · filed 2021-05-06
$87.62M
derived: sum of 2 quarters · filed 2022-02-24
$130.97M
derived: sum of 3 quarters · filed 2022-02-24
$133.34M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$84.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$127.92M
derived: sum of 2 quarters · filed 2022-02-24
$130.29M
derived: sum of 3 quarters · filed 2022-02-24
$131.82M
10-K · filed 2022-02-24
2019-09-30$43.35M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$45.72M
derived: sum of 2 quarters · filed 2020-11-06
$47.26M
10-Q · filed 2020-11-06
$77.61M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$2.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$3.90M
10-Q · filed 2020-08-07
$34.25M
derived: sum of 3 quarters · filed 2021-02-26
$35.49M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$1.53M
10-Q · filed 2020-05-08
$31.89M
derived: sum of 2 quarters · filed 2021-02-26
$33.13M
derived: sum of 3 quarters · filed 2021-02-26
$35.79M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31$30.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
$31.59M
derived: sum of 2 quarters · filed 2021-02-26
$34.26M
derived: sum of 3 quarters · filed 2021-02-26
$86.94M
10-K · filed 2021-02-26
2018-09-30$1.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$3.91M
derived: sum of 2 quarters · filed 2019-11-12
$56.59M
10-Q · filed 2019-11-12
$115.07M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$2.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$55.35M
10-Q · filed 2019-08-07
$113.83M
derived: sum of 3 quarters · filed 2020-02-26
$113.10M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$52.68M
10-Q · filed 2019-05-08
$111.16M
derived: sum of 2 quarters · filed 2020-02-26
$110.43M
derived: sum of 3 quarters · filed 2020-02-26
$110.12M
derived: sum of 4 quarters · filed 2020-02-26
2017-12-31$58.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$57.75M
derived: sum of 2 quarters · filed 2020-02-26
$57.44M
derived: sum of 3 quarters · filed 2020-02-26
$154.53M
10-K · filed 2020-02-26
2017-09-30-$730.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$1.04M
derived: sum of 2 quarters · filed 2018-11-08
$96.06M
10-Q · filed 2018-11-08
$95.52M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$309.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$96.78M
10-Q · filed 2018-08-07
$96.25M
derived: sum of 3 quarters · filed 2019-03-01
$96.22M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$97.09M
10-Q · filed 2018-05-04
$96.56M
derived: sum of 2 quarters · filed 2019-03-01
$96.53M
derived: sum of 3 quarters · filed 2019-03-01
2016-12-31-$538.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$560.00K
derived: sum of 2 quarters · filed 2019-03-01
$97.16M
10-K · filed 2019-03-01
2016-09-30-$22.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$97.70M
10-Q · filed 2017-11-08
2016-06-30$97.72M
10-Q · filed 2017-08-09
2015-12-31$139.39M
10-K · filed 2018-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30